Sanofi shares jump on positive ‘smoker’s lung’ drug data
Sanofi and Regeneron's US-listed shares head higher in premarket. Sanofi’s asthma drug Dupixent, jointly developed with Regeneron, met all targets in a trial to treat "smoker's lung". Sanofi’s shares soared almost 5% in France.
Sanofi, Regeneron US-listed shares gain in premarket
Sanofi and Regeneron Pharmaceuticals Inc are two drug stocks likely to soar at the Wall Street open. They are both tracking higher in premarket. If you're looking for an 'in' point, this could be your chance.
Dupixent
Sanofi's had positive results from this drug used in trials to treat asthma, among other things. Dupixent met all targets in a trial to treat "smoker's lung", potentially adding billions to the French drugmaker's growth prospects.
Share reaction
Sanofi's shares jumped in Paris. Regeneron's US-listed shares are up some 5% while Sanofi's US-listed shares are 6% higher premarket.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Forex
- Shares
- Indices
